

Azithromycin

Section	Indications
Watch group antibiotics Oral > Liquid: 200 mg per 5 mL oral liquid Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule	First choice co-prescribed with ceftriaxone Gonococcal infection Second choice co-prescribed with cefixime Gonococcal infection

Cefepime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefixime

Section	Indications
Watch group antibiotics Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	Second choice Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	Bacterial infection of unspecified site

Ceftazidime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

co-prescribed with [vancomycin](#)

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

co-prescribed with [metronidazole](#)

[Necrotising fasciitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Delafloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Erythromycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Bacterial infection of unspecified site

Fourth generation cephalosporins

Section

Watch group antibiotics

.

Indications

Other specified bacterial diseases

Imipenem + cilastatin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for

Neutropenia (high-risk)

Therapeutic equivalent to [meropenem](#) for

Peritoneal abscess (severe)

Therapeutic equivalent to [meropenem](#) for

Peritonitis (severe)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant *Acinetobacter baumannii*

Meropenem

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Piperacillin + tazobactam

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Peritoneal abscess (severe)

Neutropenia (high-risk)

Peritonitis (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Vancomycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Indications

First choice

co-prescribed with [ceftazidime](#)

Endophthalmitis

co-prescribed with [ceftriaxone](#)

Endophthalmitis

Other indications

Methicillin resistant *Staphylococcus aureus*